Physician profile
John C Randolph
NPI 1164621330
$3,878.00
in general payments reported to CMS, 2019-2025
25 companies · $1,176 in 2025
The $1,176 reported for 2025 was more than what 81% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $295 · 2020: $65.82 · 2021: $152 · 2022: $482 · 2023: $749 · 2024: $958 · 2025: $1,176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,883.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,882.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,226.83 | 2019-2025 | Eylea Hd, Eylea |
| Astellas Pharma US INC | $456.20 | 2023-2025 | Izervay |
| Genentech USA, INC. | $418.77 | 2022-2025 | Vabysmo, Lucentis |
| Abbvie INC. | $265.22 | 2022-2025 | |
| Apellis Pharmaceuticals, INC. | $211.57 | 2022-2025 | Syfovre |
| Harrow Eye, LLC | $206.64 | 2025 | Iheezo, Triesence |
| Notal Vision, INC. | $172.93 | 2022 | |
| Allergan, INC. | $148.22 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $118.12 | 2019-2021 | |
| Alcon Vision LLC | $117.48 | 2025 | Precision7, Unity |
| Tarsus Pharmaceuticals, INC. | $95.81 | 2024 | Xdemvy |
| Coherus Oncology, INC. | $82.20 | 2023-2024 | |
| Sandoz INC. | $59.14 | 2024-2025 | Cimerli |
| Mallinckrodt Hospital Products INC. | $58.51 | 2025 | Acthar |
| Bausch & Lomb Americas INC. | $57.66 | 2022-2025 | Xipere |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $52.70 | 2023 | Eylea |
| Dutch Ophthalmic, USA | $32.64 | 2024 | Eva, Combined Machine, Tissueblue |
| Neurotech Pharmaceuticals, INC. | $29.97 | 2025 | |
| Biogen, INC. | $23.73 | 2023 | |
| Ocular Therapeutix, INC. | $22.44 | 2025 | Dextenza |
| Alimera Sciences, INC. | $21.22 | 2024 | Yutiq, Iluvien |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Randolph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.